Licensed vaccines (Ervebo, Zabdeno/Mvabea) protect against Zaire ebolavirus only — no licensed vaccine yet covers Bundibugyo. Prevention of BDBV relies on rapid case detection, contact tracing, safe burials, PPE, and ring vaccination with investigational candidates.
Two vaccines are licensed against Ebola: Ervebo (rVSV-ZEBOV), a single-dose live vaccine approved in 2019, and the two-dose Zabdeno/Mvabea (Ad26.ZEBOV + MVA-BN-Filo) regimen approved in 2020. Both were developed and tested against Zaire ebolavirus. Neither carries a label indication for Bundibugyo ebolavirus (BDBV), meaning their efficacy against the current outbreak strain is unproven.
Ring vaccination — immunising contacts of confirmed cases and their contacts — was the strategy that helped end the 2018-2020 DRC Ebola outbreak. For the current BDBV outbreak, ring vaccination with investigational BDBV-targeting candidates is being deployed under expanded-access or compassionate-use protocols, but efficacy data remain limited.
Personal protective equipment (PPE) is the first line of defence in healthcare settings. Full barrier nursing — fluid-resistant gown or coverall, double gloves, face shield or goggles, N95 respirator or PAPR, waterproof apron, and boot covers — must be worn during any contact with suspected or confirmed patients. Proper doffing procedures are critical; most healthcare worker infections occur during removal of contaminated gear.
Safe and dignified burials are essential. Traditional funeral practices — washing, touching, and kissing the body — are among the highest-risk transmission events. Trained burial teams in full PPE perform decontamination, place the body in a sealed bag, and ensure the family can observe rituals at a safe distance. Community engagement to adapt these protocols culturally has proven decisive in past outbreaks.
Contact tracing and active surveillance form the backbone of outbreak control. Every confirmed case triggers identification of all contacts within the previous 21 days. Contacts are monitored daily for fever and symptoms; those who become symptomatic are immediately isolated and tested. Digital tools and community health workers accelerate this process.
Infection prevention and control (IPC) in health facilities includes triage screening at entry, isolation wards with dedicated staff, safe waste management (incineration of contaminated materials), and decontamination of surfaces with 0.5% chlorine solution. Hospitals without adequate IPC have historically amplified Ebola outbreaks dramatically.
Community engagement and risk communication are as important as biomedical tools. Distrust of health authorities, misinformation, and resistance to isolation have derailed control efforts in past outbreaks. Involving community leaders, religious figures, and survivors as trusted messengers improves cooperation with surveillance, vaccination, and burial teams.
Border screening and movement monitoring help limit geographic spread. Thermal scanners and symptom questionnaires at airports, land crossings, and river ports provide an early warning layer, though they cannot catch people still in the incubation period.
Research priorities for BDBV prevention include accelerating clinical trials of cross-protective or BDBV-specific vaccines, developing rapid point-of-care diagnostics that distinguish BDBV from other filoviruses, and building regional stockpiles of PPE and decontamination supplies in areas at highest risk of spillover.